Fig. 4

HA-ML@ES NPs can restore HUVECs function. (A) HA-ML@ES NPs repair HUVECs pattern diagram. (B) Volcano plots of differentially expressed genes distribution in HUVECs treated with Hcy and HA-ML@ES NPs. [Hcy] = 100 µM. (C) KEGG analysis of upregulated and downregulated cellular pathways in HUVECs caused by HA-ML@ES NPs. (D) Flow cytometry analysis and (E) quantitative analysis of HUVECs apoptosis. [Hcy] = 100 µM. (F) Western blot assay and (G) quantitative analysis of BAX, Bcl-2, and Cleaved caspase-3 levels in HUVECs with different treatments. [Hcy] = 100 µM. (H) CLSM images of ICAM-1 and VE-cad on HUVECs with different treatment. [Hcy] = 100 µM. Scale bar = 50 μm. (I) Quantitative analysis of ICAM-1 staining. (J) Quantitative analysis of ICAM-1 staining. (K) ECAR profile showing glycolytic function of glycolytic function parameters in HUVECs under different treatment. [Hcy] = 100 µM. Vertical lines indicate the time of addition of glucose (10 mM), oligomycin (1 µM), and 2-DG (50 mM) (n = 3). (L) CLSM images of PKM2 in HUVECs with different treatment. Scale bar = 50 μm. (M&N) Measurement of L-lactic acid APT content in HUVECs. Date are mean ± SD (n = 3) *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001